PhaseBio to Present at the Stifel 2020 Virtual Healthcare Conference on November 18th
PhaseBio Pharmaceuticals (NASDAQ: PHAS) will have its CEO, Jonathan P. Mow, participate in a fireside chat during the Stifel 2020 Virtual Healthcare Conference on November 18, 2020, at 11:20 a.m. EST. The event can be accessed via a live webcast on the company’s website under the “Investors” section. A replay will be available for 90 days post-event.
PhaseBio focuses on developing novel therapies for cardiovascular and cardiopulmonary diseases, including PB2452, PB1046, and PB6440, leveraging their elastin-like polypeptide technology.
- None.
- None.
MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)--PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases, today announced that Chief Executive Officer Jonathan P. Mow will participate in a fireside chat during the Stifel 2020 Virtual Healthcare Conference on Wednesday, November 18, 2020, at 11:20 a.m. EST.
The event will be available via live webcast from the “Events and Presentations” page of the “Investors” section of the company’s website at www.phasebio.com. The webcast replay will be available for 90 days after the conclusion of the live presentation.
About PhaseBio
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases. The company’s pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor; pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. PhaseBio’s proprietary elastin-like polypeptide technology platform enables the development of therapies with potential for less-frequent dosing and improved pharmacokinetics, including pemziviptadil, and drives both internal and partnership drug-development opportunities.
PhaseBio is located in Malvern, PA, and San Diego, CA. For more information, please visit www.phasebio.com.
